Kornimate/medical-research-clean huggingface dataset:
use of hyaluronic acid injection in lateral patellar compression with femoral condylar degenerative changes after arthroscopic release

Conditions: Anterior Knee Pain Syndrome

Summary: ninety patients are involved in this study, who underwent arthroscopic lateral patellar release for lateral patellar compression syndrome and they had patellofemoral degenerative lesion, which diagnoses by mri preoperatively and proved by arthroscopic examination to be early stages of degenerative changes with no loss of articular surface. the patients were divided in to two groups (a and b). group a (45 patients) were treated by local injection of hyaluronic acid intraarticularly, and group b (45 patients) were no injection intraarticular.

this study was done by one orthopedic surgeon in two hospitals. ninety patients are involved in this study, who underwent arthroscopic lateral patellar release for lateral patellar compression syndrome and they had patellofemoral degenerative lesion, which diagnoses by mri preoperatively and proved by arthroscopic examination to be early stages of degenerative changes with no loss of articular surface. the patients were divided in to two matched groups (a and b) regarding the age and gender; group a (45 patients) were treated by local injection of hyaluronic acid intraarticularly, 2 weeks after arthroscopy and were followed by vas of knee pain for one year at (3) months, (6) months and (12) months, and group b (45 patients) were no injection intraarticular. the study started on june (2017) and ends on march (2020). injection of hyaluronic acid was used and followed in the same way. all patients presented with anterior knee pain which failed to respond to conservative treatment for 6 weeks or recurrent of symptoms after stopping of conservative treatment which involved changes of life style and nsaid. mri done for all patients before operation.

Eligibility criteria:
inclusion criteria: * lateral patellar compression syndrome exclusion criteria: * patellar instability. * smoking. * diabetes mellitus. * previous knee surgery.

Keywords: hyaluronic acid injection knee arthroscopy lateral patellar retinaculae. lateral patellar compression syndrome
ancrod (viprinex™) for the treatment of acute, ischemic stroke

Conditions: Stroke; Cerebral Ischemia; Brain Infarction

Summary: the primary purpose of this study is to determine whether a brief intravenous infusion of ancrod started within 6 hours of stroke onset improves functional outcome at 3 months.

with prior approval by the fda, an interim analysis for futility was performed when 500 subjects had been entered into the two parallel trials, nct00141001 and nct00300196. the analyses were reviewed by the data safety monitoring board, which recommended that both studies be terminated because of futility. this was done at a point where 650 subjects had been entered into both studies, combined, but analyses were conducted only on the initial 500 subjects. results of the abbreviated analysis will be found with study nct00141001 since that study contributed most of the subjects to the analysis.

Eligibility criteria:
inclusion criteria: * acute, ischemic stroke with first symptoms within 6 hours of beginning treatment * baseline nihss \> 5 exclusion criteria: * no intracranial, extravascular blood on ct * hypertension (systolic \> 185; diastolic \> 105) * baseline fibrinogen level \< 100 mg/dl * thrombocytopenia (\< 100,000 / mm3) * recent (\< 3 days) or anticipated (\< 5 days) use of a thrombolytic agent * recent (\< 14 days) or anticipated surgery

Keywords: stroke fibrinogen reperfusion thrombolysis
effectiveness of pilates in patients with subacute low back pain

Conditions: Subacute Low Back Pain

Summary: this study aims to evaluate the effectiveness of pilates exercises in patients with subacute low back pain, which typically lasts between 4 and 12 weeks. subacute low back pain is longer-lasting than acute pain and can negatively impact daily activities and quality of life. pilates is an exercise method that strengthens core muscle groups, improves flexibility, and supports body balance. this research is designed as a comparative study between two groups. one group will participate in pilates exercises, while the other group will follow a standard home exercise program. the study will assess outcomes such as pain level, mobility, and quality of life. through this, the study aims to provide more insights into the potential of pilates as a treatment method for subacute low back pain.

this study investigates the role of pilates exercises in managing subacute low back pain, a condition defined as lasting between 4 and 12 weeks. subacute low back pain often disrupts daily functioning and lowers quality of life, and effective interventions during this stage are crucial to prevent the transition to chronic pain. pilates has been suggested as a beneficial exercise approach due to its focus on core stability, flexibility, and balanced body mechanics, which may reduce pain and improve functional outcomes in low back pain patients. participants in the study will be divided into two groups: a pilates group and a home exercise group. the pilates group will participate in a structured pilates program designed to target core muscle strength and flexibility over a set period, while the home exercise group will follow a standard exercise program tailored for general low back pain relief. both groups will perform their respective exercises for eight weeks. the primary outcome measures will include pain intensity, physical function, and quality of life, assessed at baseline, post-treatment, and follow-up periods. the findings from this study will contribute to understanding whether pilates can be a valuable addition to conservative treatment approaches for subacute low back pain.

Eligibility criteria:
inclusion criteria: * adults aged between 18 and 65 years.d * diagnosis of subacute low back pain, defined as pain lasting between 6 and 12 weeks * no previous pilates experience. exclusion criteria: * history of spinal surgery or significant spinal deformities (e.g., scoliosis). * presence of serious medical conditions such as cardiovascular disease, uncontrolled hypertension, or neurological disorders. * pregnancy or planned pregnancy during the study period. * use of pain-relief medications that could interfere with the results of the study. * participation in any structured physical therapy program in the last three months.

Keywords: pilates subacute low back pain
study to evaluate the safety of chronic administration of simulect to subjects receiving a first kidney transplant

Conditions: End Stage Renal Disease

Summary: the study is undertaken to explore the safety of using simulect at monthly dose intervals to reduce the need of high dose/level cni's such as prograf.

the use of cni's after kidney transplantation is associated with typical adverse effects such as potential contribution to progressive impairment of renal function, hypertension, and metabolic abnormalities. the study consists of a run-in phase (1 month),and treatment phase (11 months) and safety assessment phase (1 month).

Eligibility criteria:
inclusion criteria: * male or female 18-75 * first kidney transplant from a living or deceased donor * receiving cni and mpa * able to tolerate full dose mpa * calculated glomerular filtration rate \>=30ml/min by cockcroft-gault equation * able to tolerate renal graft biopsies * provided written, informed consent * females of childbearing potential must have a negative pregnancy test within 48 hours prior to the first simulect administration exclusion criteria: * known hypersensitivity to simulect * current preformed pra\>10% * multi organ or second kidney transplant * use of any investigational immunosuppressive drug within 1 month of inclusion * female patients who are pregnant, lactating or of child bearing potential and not practicing two approved methods of birth control * known malignancy or history of malignancy other than excised basal or squamous cell carcinoma of the skin * hbv, hcv, or hiv positive patients * current severe infection * receiving an organ from an extended criteria donor per united network for organ sharing (unos) guidelines * dialysis dependent one month post transplant * live too far away from the transplant center for adequate follow up

Keywords: simulect de novo kidney transplant subjects calcineurin inhibitors prograf
preventing depression in patients with macular degeneration

Conditions: Depression; Macular Degeneration

Summary: this study will evaluate the effectiveness of a problem solving treatment in preventing depression in elderly patients with age-related macular degeneration (amd).

amd is the most common cause of blindness in older adults. the disease limits the ability to read, see familiar faces, and walk independently. almost 2 million persons (about 5 percent of the u.s. population over age 65) are now affected, and this number will triple by the year 2020. this study will target patients with neovascular amd (nv-amd), a form of amd which can lead to sudden vision loss, substantial disability, and depression. because depression is itself disabling and not likely to be recognized nor treated by ophthalmologists, preventing depression in people with nv-amd is important. patients are randomly assigned to either pst or a usual care control condition. the primary outcome measure is a dsm-iv diagnosis of depression. patients are evaluated at baseline, month 2 (immediately post-intervention), month 6 (for the primary efficacy analysis), and month 12 (to evaluate sustained effects). the study will also assess the impact of pst on levels of disability and vision-related quality of life.

Eligibility criteria:
inclusion criteria: * bilateral macular degeneration * visual acuity of 20/40 or worse in better eye * residence within 40 miles of wills eye hospital in philadelphia, pa

Keywords: depressive disorder blindness aged
metals and in fetal growth restriction

Conditions: Fetal Growth Restriction

Summary: introduction: intrauterine fetal growth restriction (fgr) is a condition in which the fetus does not realize its growth potential in the uterus. heavy metals important pollutants produced from anthropogenic activities, has been suggested to be embryotoxic and fetotoxic in a lot of studies. however, the causes of fetal growth restriction are little known and heavy metals merit further investigation. the investigators will be tested whether fetal growth restriction was associated with exposure to these metals/vitamins. methods: this study was designed to determine maternal plasma/urine/hair, cord plasma, placenta and breast milk tin (sn), manganese (mn), vanadium (v), magnesium (mg), cobalt (co), nickel (ni), arsenic (as), chromium (cr), cadmium (cd), lead (pb), mercury (hg), antimony (sb), aluminium (al), zinc (zn), copper (cu), selenium (se), iron (fe), vitamin d, vitamin a, vitamin b12 and folate concentrations in women with fgr (n=55) compared to those of volunteer healthy pregnant women (n=55). these heavy metals concentrations measured using inductively coupled plasma-mass spectrometry were compared.

this observational case-control study will be conducted at the department of obstetrics and gynecology, cengiz gokcek public hospital, gaziantep, turkey, between may 2020 and february 2021. the protocol was approved by the ethics committee for clinical research of gaziantep university (reference no: 2020/131). the study strictly will be adhered to the principles of the declaration of helsinki. all subjects will be included in the study gave oral and written informed consent. fgr was defined as an estimated fetal weight (grams) less than the 10th percentile for gestational age. hadlock i formula were used to calculating estimated fetal weight percentiles. every woman in the study population will be undergone obstetric ultrasound/doppler examination and fetal-maternal assessment will be carried out. then, this study will be determined maternal plasma/urine/hair, cord plasma, placenta and breast milk tin (sn), manganese (mn), vanadium (v), magnesium (mg), cobalt (co), nickel (ni), arsenic (as), chromium (cr), cadmium (cd), lead (pb), mercury (hg), antimony (sb), aluminium (al), zinc (zn), copper (cu), selenium (se), iron (fe), vitamin d, vitamin a, vitamin b12 and folate concentrations in women with fgr (n=55) compared to those of volunteer healthy pregnant women (n=55).

Eligibility criteria:
inclusion criteria: * pregnant women complicated with fetal growth restriction * healthy pregnancy * singleton pregnancy exclusion criteria: 1. pregnant women with any systemic condition (such as chronic hypertension, renal disease and ) 2. women who have dyed their hair in the last 9 months 3. history of using any medication 4. presence of gestational hypertension or gestational diabetes 5. drug user 6. patients who had fetal congenital abnormalities or genetic syndromes 7. multiple-gestation pregnancies 8. intrauterine fetal death
colonic gallstone ileus, diagnostic-therapeutic algorithm

Conditions: Gall Stone

Summary: gallstone ileus is a rare complication of gallstone disease. there is no systematic review on cgi. we analyze published literature on the subject and plan to propose a diagnostic-therapeutic algorithm for cgi. following the preferred reporting items for systematic reviews and meta-analysis (prisma) and amstar (assessing the methodological quality of systematic reviews) guidelines, we will performe a systematic review of english-, german-, spanish-, japanese-, and italian-language articles using pubmed (1946-2021), pubmed central (1900-2021), and google scholar. the search items include 'gallstone ileus', 'colonic gallstone ileus', 'gallstone coleus', 'cholecystocolonic fistula', 'ileo biliar', 'iléus biliaire', 'ileo di calcoli biliary', 'galsteen ileus', 'fístula colecistocolônica', 'fistule cholécystocolique'. additional studies will be identified by reviewing reference lists of retrieved studies. we will include all cases and case series with a complete description of cgi. exclusion criteria: (1) small bowel gallstone ileus; (2) gastric outlet gallstone ileus; (3) non-gallstone intraluminal obstruction; and (4) cholecystocolonic fistula without cgi. the primary outcome: a relationship of demographic data, gallstone size, symptoms, obstruction level, risk factors, and comorbidities (biliary history, diverticular disease, cardiovascular disease, radiation of pelvis), diagnostics (palpable mass in the abdomen and rectal exam, laboratory tests, sigmoidoscopy/colonoscopy, x-ray, computed tomography (ct), colonic rigler's triad) with the correct diagnosis. the secondary outcome: the identification of therapeutic options and related survival. the third outcome: to develop a comprehensive diagnostic-therapeutic algorithm for cgi. the study is exempt from ethics approval because we synthesized data from published studies.


Eligibility criteria:
inclusion criteria: * all published cases and case series with a complete description of colonic gallstone ileus exclusion criteria: * small bowel gallstone ileus; gastric outlet gallstone ileus; non-gallstone intraluminal obstruction; and cholecystocolonic fistula without colonic gallstone ileus

Keywords: gallstone ileus cholecystocolonic fistula risk factors diagnosis therapy algorithm
carto-finder guided ablation versus multiscale entropy guided ablation in persistent atrial fibrillation

Conditions: Persistent Atrial Fibrillation

Summary: this is a randomized control trial to compare the efficacy and safety of carto-finder-guided ablation plus pulmonary vein isolation versus multiscale entropy (mse)-guided pulmonary vein isolation in patients with persistent atrial fibrillation.

this is a randomized control trial. patients with persistent atrial fibrillation are enrolled and randomized to carto-finder-guided ablation plus pvi group or mse-guided ablation plus pvi group. postoperative recurrence rate and other indicators are analyzed to compare the efficacy and safety between carto-finder-guided ablation plus pvi and mse-guided ablation plus pvi in patients with persistent atrial fibrillation.

Eligibility criteria:
inclusion criteria: 1. aged 18 to 80 years old 2. persistent af 3. nonresponse or intolerance to ≥1 antiarrhythmic drug exclusion criteria: 1. with uncontrolled congestive heart failure; 2. having significant valvular disease; 3. having moderate-to-severe pulmonary hypertension; 4. with myocardial infarction or stroke within 6 months of screening; 5. with significant congenital heart disease; 6. ejection fraction was \<40% measured by echocardiography; 7. allergic to contrast media; 8. contraindication to anticoagulation medications; 9. severe pulmonary disease e.g. restrictive pulmonary disease, chronic obstructive disease (copd); 10. left atrial thrombus; 11. having any contraindication to right or left sided heart catheterization

Keywords: persistent atrial fibrillation catheter ablation carto-finder-guided ablation multiscale entropy-guided ablation
safety and efficacy of a new therapy as adjunctive therapy to anti-vascular endothelial growth factor (anti-vegf) in subjects with wet age-related macular degeneration (amd)

Conditions: Choroidal Neovascularization; Age-Related Maculopathy

Summary: the study will evaluate the safety and efficacy of the intravitreal dexamethasone implant as adjunctive therapy to anti-vegf treatment in the study eye of treatment naïve subjects with choroidal neovascularization secondary to age-related macular degeneration. subjects will be followed for 26 weeks.


Eligibility criteria:
inclusion criteria: * 50 years of age or older with active subfoveal choroidal neovascularization (cnv) secondary to amd * central retinal thickness ≥ 300 µm * visual acuity between 20/400 and 20/32 * eligible for anti-vegf therapy exclusion criteria: * previous treatment for cnv due to amd * high eye pressure * glaucoma * uncontrolled systemic disease * known allergy to the study medications * recent eye surgery or injections in the eye * female subjects that are of childbearing potential
temozolomide in preventing brain metastases in small cell lung cancer

Conditions: Small Cell Lung Cancer; Metastatic Carcinoma

Summary: to investigate the response of temozolomide versus prophylactic cranial radiotherapy in preventing brain metastases in completed or partial remission limited small cell lung cancer patients.

we'd like to investigate the 2-year incidence rate of brain metastases in completed or partial remission limited small cell lung cancer patients who received temozolomide only for 12 months or 25-30gy prophylactic cranial radiotherapy in preventing brain metastases.

Eligibility criteria:
inclusion criteria: 1. histological or cytological diagnosis of small-cll lung cancer histology 2. 18 years or older 3. eastern cooperative oncology group (ecog) performance status no more than 2 4. local stage sclc without distant metastases 5. after 1st-line chemotherapy (ep or ip) at least 4 cycles 6. after radical radiotherapy for primary tumor and lymph node drainage area:including concurrent or sequence chemoradiotherapy 7. cr or pr assessment by recist(1.0) before randomized 8. haemoglobin 10.0 g/dl, absolute neutrophil count (anc) 1.5\^9/l, platelets 100 x 10\^9/l 9. total bilirubin 1.5 x upper limit of normal (uln) alanine aminotransferase (alt) and aspartate aminotransferase (ast) \< 2.5 x uln in the absence of liver metastases, or \< 5 x uln in case of liver metastases 10. creatinine clearance 60ml/min (calculated according to cockcroft-gault formula) exclusion criteria: 1. mixed non-small cell lung cancer histology 2. neck and supraclavicular lymph node metastasis 3. be allergic to temozolomide or intolerable to radiotherapy 4. any unstable systemic disease 5. pregnant or lactating women

Keywords: limited small cell lung cancer brain metastases prophylactic cranial radiotherapy temozolomide
nomograms for optimization of amikacin first dose in critically ill patients using a population pharmacokinetics model

Conditions: Pharmacokinetics

Summary: the aim of this study is to elaborate nomograms to optimize amikacine first dosing in critically ill patients, using a population pharmacokinetics model elaborated with multicentric data.

french guidelines recommend for probabilistic therapy to reach an amikacin concentration 1 hour after beginning the infusion ≥ 60 mg/l. this target is rarely achieved in the icu despite a 30 mg/kg recommended dosage. using data collected prospectively in critically ill patients of nîmes (france) (1) and nantes (france), we will elaborate a population pharmacokinetic model on the non-parametric software pmetrics and on the parametric software monolix. we will calculate probability of target attainment of monte-carlo simulations, using the non-parametric model. nomograms to determine optimal first dose of amikacin in critically ill patients, according to a few variables previously identified, will be produced.

Eligibility criteria:
inclusion criteria: * patients treated with amikacin for sepsis in one of the participating icu will be included. exclusion criteria: * patients with aminoglycoside allergy, history of myasthenia, pregnancy, under guardianship.

Keywords: amikacin
effects of rosiglitazone on plasma bnp levels and left ventricular dysfunction

Conditions: Diabetes Mellitus, Type 2

Summary: the present study aimed to evaluate the effect of rosiglitazone treatment on cardiac function compared with metformin

large scale clinical trials have reported fluid retention and increase in plasma volume (6% to 7%) with glitazone therapy, with an increased incidence of peripheral edema occuring in 2% to 5% patients. some evidence suggests that this effect may be related to increased endothelial cell permeability induced by glitazones therapy. others report that glitazones may interfere with renal hemodynamics. in controlled clinical trials, the frequency of new onset congestive heart failure was very low in glitazones treated patients. the incidence of congestive heart failure is higher in patients receiving combination therapy with insulin and glitazones. only few studies compared rosiglitazone and metformin on cardiac safety. recently a study reported a reversible increase in endothelial cell permeability to albumin in cultured pulmonary arterial cells treated with rosiglitazone. to our knowledge, there is not any clinical study published for showing the reversibility of the cardiac adverse effects if the rosiglitazone treatment is continued.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus treated with oral hypoglycemic agents or diet only * without any symptom or finding of heart failure * normal liver enzymes and renal functions exclusion criteria: * any known coronary artery disease, congestive hearth failure, renal disease or liver disease * any treatment for heart failure or diuretics for any reasons.

Keywords: natriuretic peptide, brain heart failure, congestive